✦ LIBER ✦

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

✍ Scribed by Takahashi, Naoto; Miura, Masatomo; Kuroki, Jun; Mitani, Kinuko; Kitabayashi, Atsushi; Sasaki, Osamu; Kimura, Hideo; Imai, Kiyotoshi; Tsukamoto, Norifumi; Noji, Hideyoshi; Kondo, Takeshi; Motegi, Mutsuhito; Kato, Yuichi; Mita, Masayuki; Saito, Hajime; Yoshida, Chikashi; Torimoto, Yoshihiro; Kimura, Tomofumi; Wano, Yuji; Nomura, Jun; Yamamoto, Satoshi; Mayama, Ko; Honma, Riko; Sugawara, Tomohiro; Sato, Shinji; Shinagawa, Atsushi; Abumiya, Maiko; Niioka, Takenori; Harigae, Hideo; Sawada, Kenichi

Book ID: 125405020
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 344 KB
Volume: 2
Category: Article
ISSN: 2050-7771
DOI: 10.1186/2050-7771-2-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH